
    
      Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with
      a clinical follow-up between (a) 12 and 14 weeks and (b) 22 and 24 weeks.

      The RABIOPRED test is indicated for use in patients:

        -  18 years of age or older,

        -  Eligible for a first line biologic therapy with anti-TNF alpha. The RABIOPRED test is
           indicated for use by rheumatologists as a biological basis for guiding anti-TNF alpha
           treatment prior to its initiation.
    
  